MATRIXLABS

DSP Merrill Lynch Ltd has informed the Exchange regarding a Public Announcement on the delay in the opening of the open offer to the public shareholders of Matrix Laboratries Ltd, which has been published on October 20, 2006 in the newspaper. The copy of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Matrix_PA_26102006.zip target=NEW> For more details click here.</a>

Matrix Laboratories Limited has informed the Exchange that the Members of the Company at their AGM of the Company held on September 25, 2006 considered and unanimously approved all the resolutions contained in the Notice of the AGM. A copy of the outcome of AGM shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/matrix_nse_250906.zip target=NEW> For more details click here.</a>

Matrix Laboratories Limited has informed the Exchange regarding a press release, dated, September 22, 2006, titled "Matrix Laboratories Ltd. signs Licensing Agreement with Gilead". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/matrix_nse_220906.zip target=NEW> For more details click here.</a>

Matrix Laboratories Limited has informed the Exchange that the share allotment committee at its meeting held on September 19, 2006, have allotted 1,60,635 Equity Shares of Rs. 2/- each under ESOP - 2004 Scheme. Consequent to the above allotment, the paid - up capital of the Company has increased to Rs. 30,79,32,420/-.

Therefore, the Acquirer along with the PAC, is making an offer to public shareholders of Matrix ("Shareholders") to acquire up to 30,831,962 voting equity shares ("Share(s)") of Rs. 2 each, representing in the aggregate 20.0% of the fully diluted voting equity shares capital of Matrix at a price of Rs. 306 (Rupees three hundred six only) per share ("Offer Price"), payable in cash and subject to the terms and conditions mentioned hereinafter ("Offer"). The Acquirer will purchase all the Shares tendered and accepted under this Offer, subject to certain conditions and other terms and conditions s

Matrix Laboratories Limited had informed the Exchange that the share allotment committee at its meeting held on August 28, 2006, have allotted 50,250 Equity Shares of Rs. 2/- each under ESOP - 2004 Scheme. Consequent to the above allotment, the paid - up capital of the Company has increased to Rs. 30,76,11,150/-. The company has now informed the Exchange that the date of share allotment committee meeting is August 27,2006 and not August 28,2006 as mentioned above.

DSP Merrill Lynch Ltd has informed the Exchange regarding the Public Announcement (the "PA") being issued by DSP Merrill Lynch Limited ("Manager to the Offer"/"DSPML"), on behalf of MP Laboratories (Mauritius) Ltd. (hereinafter referred to as "Acquirer"), and Mylan Laboratories Inc. (hereinafter referred to as "Mylan" / "Persons acting in concert" / "PAC") pursuant to Regulation 10 and 12 of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulation, 1997 (the "SEBI(SAST) Regulation"). The Acquirer, a company with limited liability, incorporated und

Matrix Laboratories Limited has informed the Exchange that the share allotment committee at its meeting held on August 28, 2006, have allotted 50,250 Equity Shares of Rs. 2/- each under ESOP - 2004 Scheme. Consequent to the above allotment, the paid - up capital of the Company has increased to Rs. 30,76,11,150/-.

Matrix Laboratories Limited has informed the Exchange that the key shareholders of the Company viz., Mr. N. Prasad, India Newbridge Investments Limited, Maxwell (Mauritius) Pte Limited, India Newbridge Coinvestment Limited and India Newbridge Partners FDI Limited and others have entered into agreements with Mylan Laboratories Inc., USA, for sale of their shareholding in Matrix aggregating to 51.54% of the Company's paid-up share capital. In this regard, the Board of Directors of the Company at their meeting held on August 28, 2006 have approved execution of the following agreements with Mylan

Matrix Laboratories Limited has informed the Exchange that the share allotment committee at its meeting held on August 17, 2006, have allotted 99,810 Equity Shares of Rs. 2/- each under ESOP - 2004 Scheme. Consequent to the above allotment, the paid - up capital of the Company has increased to Rs. 30,75,10,650/-.

News Verification : The media had reports that Matrix Laboratories Limited is likely to pick up some stake in Granules India Limited. The Exchange, in order to verify the accuracy or otherwise of the information reported in the media and to inform the market place so that the interest of the investors is safeguarded, had written to the officials of the company. Matrix Laboratories Limited has vide its letter inter-alia stated, "We deny the aforesaid news, as it is incorrect and baseless."

Matrix Laboratories Limited has informed the Exchange regarding a press release, dated, July 27, 2006, titled "Matrix records net sales of Rs. 4422 million and net profit of Rs.338 million for Q1FY07". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).

Matrix Laboratories Limited has informed the Exchange that the BOD's at their meeting held on July 27, 2006, considered and approved the following business: 1) Closure of Register of Members and Share Transfer Books from September 20, 2006 to September 25, 2006 for the purpose of AGM and dividend; 2) To convene and conduct AGM of the Company on September 25, 2006.

News Verification : The media had reports that US-based Mylan Laboratories is in advanced talks with promoters and private equity funds to buy a majority stake in Matrix Laboratories Limited. The Exchange, in order to verify the accuracy or otherwise of the information reported in the media and to inform the market place so that the interest of the investors is safeguarded, had written to the officials of the company. Matrix Laboratories Limited has vide its letter inter-alia stated, "We deny the said news item, as it is incorrect and baseless."

Matrix Laboratories Limited has informed the Exchange regarding a press release, dated, June 10, 2006, titled "Matrix records net sales of Rs. 11586 million and net profit of Rs.1992 million for FY -06" The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).

Matrix Laboratories Limited has informed the Exchange that the Board of Directors of the Company at their meeting held on June 10, 2006 has recommended a dividend of Rs.1.20/- per equity share of Rs.2/- each, for the financial year ended March 31, 2006, subject to the approval of the members.

Matrix Laboratories Limited has informed the Exchange that the Board of Directors of the Company at their meeting held on June 10, 2006 has approved (i) Appointment of Dr. Christina Lim-Tong as an Additional Director of the Company; (ii) Acceptance of Resignation of Mr. Tan Suan Swee as a Director.

Matrix Laboratories Limited has informed the Exchange that the share allotment committee at its meeting held on May 22, 2006, have allotted 38,975 equity shares of Rs. 2/- each under ESOP - 2004 Scheme. Consequent to the above allotment the paid up capital of the Company has increased to Rs. 30,73,11,030.

Matrix Laboratories Limited has informed the Exchange that the Compensation Committee at its meeting held on May 11, 2006 have granted 1,55,000 employee stock options of Rs. 2/- each to the eligible members of the Subsidiary Companies employees under ESOP 2004.

Matrix Laboratories Limited has submitted to the Exchange a copy of the proceedings of the Extraordinary General Meeting of the Company held on March 1, 2006. The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).

Matrix Laboratories Limited has informed the Exchange that Mr. K. Jagan Mohan Rao has sold 1875 shares of the total share capital of Matrix Laboratories Limited on April 25, 2006. The mode of sale is through Stock Exchange and the shareholding of Mr. K. Jagan Mohan Rao after the said sale is nil shares of the total share capital of Matrix Laboratories Limited.

Matrix Laboratories Limited has informed the Exchange that Merrill Lynch Capital Markets Espana S.A.SV has acquired 8,80,000 shares aggregating to 0.58% of the total paid up capital of Matrix Laboratories Ltd on April 13, 2006. The mode of acquisition is through Secondary Market Purchase and the shareholding of Merrill Lynch Capital Markets Espana S.A.SV after the said acquisition is 82,64,869 shares aggregating to 5.38% of the total paid up capital of Matrix Laboratories Ltd.

Citibank, N.A. has informed the Exchange that Merrill Lynch Capital Markets Espana S.A.SV alongwith PAC: Merrill Lynch International has acquired 8,80,000 shares aggregating to 0.58% of the total paid up capital of Matrix Laboratories Ltd on April 13, 2006. The mode of acquisition is through Secondary Market Purchase and the shareholding of Merrill Lynch Capital Markets Espana S.A.SV alongwith PAC: Merrill Lynch International after the said acquisition is 8,264,869 shares aggregating to 5.38% of the total paid up capital of Matrix Laboratories Ltd.

Matrix Laboratories Limited has submitted to the Exchange the Annual Disclosure of the shareholdings of Directors / Employees of the Company in Matrix Laboratories Limited as on March 31, 2006. The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).

All times Project Ltd has informed the Exchange that they have sold 70,00,000 shares aggregating to 4.56% of the total paid up capital of Matrix Laboratories Limited on March 31, 2006. The mode of sale is through Open Market and the shareholding of All times Project Ltd after the said sale is 41,900 shares aggregating to 0.02% of the total paid up capital of Matrix Laboratories Limited.

Matrix Laboratories Limited has informed the Exchange that All times Project Ltd has sold 7000000 shares aggregating to 4.56% of the total paid up capital of Matrix Laboratories Limited on March 31, 2006. The mode of sale is through Open Market and the shareholding of All times Project Ltd after the said sale is 41,900 shares aggregating to 0.02% of the total paid up capital of Matrix Laboratories Limited. The company has further informed the Exchange that subsequent to sale of substantial holding by All time projects Ltd and also in line with their request, the Company is removing All Time Pr

Matrix Laboratories Limited has informed the Exchange that the company has received disclosure from Employees/Director regarding their shareholding in the company. The date of acquisition is March 21,2006 and the mode of acquisition is Allotment under ESOP 2004. The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).

Matrix Laboratories Limited has informed the Exchange that the share allotment committee at its meeting held on March 21, 2006, have allotted 3,94,330 equity shares of Rs.2/- each under ESOP-2004 Scheme. Consequent to the above allotment, the paid-up capital of the Company has increased to Rs.30,72,33,080.

Matrix Laboratories Limited has informed the Exchange that Mr. S. Srinivasan, Sr.Vice President of the Company has sold 2,500 shares of Matrix Laboratories Limited on March 08, 2006. The mode of sale is through Stock Exchange and the shareholding of Mr. S. Srinivasan after the said sale is 38,060 shares of Matrix Laboratories Limited.

Matrix Laboratories Limited has informed the Exchange that the Compensation Committee vide Circular Resolution dated February 27, 2006 have granted 6,66,000 employee stock options of Rs.2/- each at a price of Rs.171/- per option to the eligible employees / Director of the Company under ESOP 2004.

Matrix Laboratories Limited has informed the Exchange that the members of the Company at their EGM (EGM) held on even date considered and unanimously approved the following items of the EGM Notice dated January 30, 2006. 1) Raising of additional long term resources through GDRs / ADRs / FCCBs upto US$ 200 millions. 2) Increase in limit of Borrowing Powers. 3) Employees Stock Option Plan (ESOP - 2006) to Subsidiary Companies.

Matrix Laboratories Limited has informed the Exchange that Mr. S. Srinivasan, Sr.Vice President of the Company has sold 2000 shares of Matrix Laboratories Limited on February 14, 2006. The mode of sale is through Stock Exchange and the shareholding of Mr. S. Srinivasan after the said sale is 40560 shares of Matrix Laboratories Limited.

News Verification : The media had reports that Matrix Laboratories Limited is close to acquiring a Latin American contract research firm for $60 million. The Exchange, in order to verify the accuracy or otherwise of the information reported in the media and to inform the market place so that the interest of the investors is safeguarded, had written to the officials of the company. Matrix Laboratories Limited has vide its letter inter-alia stated, "We explicitly clarify that the Company is not involved in any form of discussions with anyone for acquiring a contract research firm in Latin Americ

Matrix Laboratories Limited has informed the Exchange that Mr. N. Prasad, Executive Chairman of the Company has sold 20,00,000 shares of Matrix Laboratories Limited on February 17, 2006. The mode of sale is through Stock Exchange and the shareholding of Mr. N. Prasad after the said sale is 1,56,70,010 shares aggregating to 10.23% of the total share capital of Matrix Laboratories Limited.

Matrix Laboratories Limited has submitted to the Exchange a copy of the Notice of the EGM of the Equity Shareholders of the Company to be held on March 01, 2006. The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).

News Verification : The media had reports on February 09, 2006 that Teva is in the final stages of acquiring Matrix Laboratories Limited. The Exchange, in order to verify the accuracy or otherwise of the information reported in the media and to inform the market place so that the interest of the investors is safeguarded, had written to the officials of the company. Matrix Laboratories Limited has vide its letter inter-alia stated, "We expressly deny the article that Teva is in the final stages of acquiring the Company".

Matrix Laboratories Limited has informed the Exchange that the Board of Directors at their meeting held on January 30, 2006 considered, approved / recommended the following business :- 1) In principle approval for raising of funds upto a maximum of US $ 200 million by way of GDR / ADR / FCCB or shares on Preferential Basis or a combination thereof, subject to approval of the shareholders. This amount shall be utilized for the repayment of its bridge and/or term loan and also to meet its future growth requirements. 2) In principle approval for considering Employee Stock Option Plan (ESOP) to th

Matrix Laboratories Limited has informed the Exchange regarding a press release dated January 30, 2006 titled "Matrix posts consolidated net profit of Rs. 100 Cr for Q3". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).

Matrix Laboratories Limited has informed the Exchange that the results of postal ballot conducted pursuant to the provisions of Section 192A of the Companies Act, 1956 read with Companies (Passing of resolution by postal ballot) Rules 2001 in respect of the Resolution for Investment in Concord Biotech Limited, Ahmedabad had been declared and the results are as follows: Resolution No. 1:- (1) Number of Valid Postal Ballot forms received - 3143; (2) Votes in favour of the Resolution - 97859512; (3) Votes against the Resolutions - 8261; (4) % of votes in favour - 99.99%; (5) Result - Approved by

Matrix Laboratories Limited has informed the Exchange that Mr. S. Srinivasan, Sr.Vice President of the Company has sold 1000 shares of Matrix Laboratories Limited on January 09, 2006. The mode of sale is through Stock Exchange and the shareholding of Mr. S. Srinivasan after the said sale is 42560 shares aggregating to 0.03% of the share capital of Matrix Laboratories Limited.

Matrix Laboratories Limited has informed the Exchange that the BODs vide circular resolution dated December 30, 2005 approved the following items: (a) Appointment of Mr. Sharad Mansukani as an Additional Director of the Company. (b) Reconstitution of Audit Committee. (c) Acceptance of resignation tendered by Dr. C Satyanarayana as a Director.

Matrix Laboratories Limited has informed the Exchange that the share allotment committee at its meeting held on December 29, 2005, have allotted 35,00,000 equity shares of Rs.2/- each on preferential basis, at a price of Rs.225 per share (including premium) to: (a) Mr. Pieter Van Rompay, 17,50,000 equity shares of Rs.2/- each and (b) Mr.Stijn Van Rompay, 17,50,000 equity shares of Rs.2/- each.

Matrix Laboratories Limited has informed the Exchange that the Equity Shares of the Company are delisted from the Hyderabad Stock Exchange w.e.f. December 15, 2005 after complying all the statutory formalities.

Matrix Laboratories Limited has informed the Exchange that the members of the Company at their EGM held on December 19,2005 considered and unanimously approved all the resolutions of the Notice including the following items :- 1) Issue of Equity Shares on Preferential Basis to Mr. Pieter Van Rompay & Mr. Stijn Van Rompay; 2) Appointment of Mr. Rajiv Malik as Director; 3) Appointment of Mr. Rajiv Malik as Chief Executive Officer of the Company; 4) Appointment of Mr. Leon Van Rompay as a Director; 5) Investment in Shares of Mchem Pharma Group Limited, China, Dafeng Mchem Pharmaceuticals Chemical

{3} Resolution No.7 :- 1) No. of Valid Postal Ballot forms received - 1031; 2) Votes in favour of the Resolution - 103607797; 3) Votes against the Resolution - 10125; 4) % of votes in favour - 99.99; 5) Result-Approved by requisite majority.

Matrix Laboratories Limited has informed the Exchange that the BODs have approved the following: a) for acquiring controlling stake in Concord Biotech Subject to approval of members. b) reconstitution of Share Allotment Committee. A copy of Press Release issue by the Company regarding the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).

Matrix Laboratories Limited has submitted to the Exchange a copy of Notice of the EGM of the Company to be held on December 19, 2005. The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/CoTmmon/Corporate Announcements).

Matrix Laboratories Limited has submitted to the Exchange a copy of the proceedings of the AGM of the Company held on August 25, 2005. The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).

Matrix Laboratories Limited has informed the Exchange that the BODs of the Company vide circular resolution have approved the following business: (1) To issue 35,00,000 equity shares of Rs.2/- each on preferential basis, subject to the approval of the members, at a price of Rs.225 per share (including premium) amounting to Rs.787.50 millions to : (a) Mr. Pieter Van Rompay, 17,50,000 equity shares of Rs.2/- each and (b) Mr. Stijn Van Rompay, 17,50,000 equity shares of Rs.2/- each. (2) To convene an EGM of the company on December 19, 2005. Details of the press release titled, "Matrix plans pre

Matrix Laboratories Limited has informed the Exchange regarding the press release issued by the company dated October 27, 2005, titled, " Matrix posts, on consolidated basis, record sales of Rs.291.58 crore and net profit of Rs.43.69 crore for Q2.' The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).